Flu B (influenza B) is one of two types of influenza virus that cause seasonal flu outbreaks in humans. Unlike influenza A, which also circulates in birds, pigs, and other animals, influenza B circulates almost exclusively among people. This matters because it means flu B cannot trigger the kind of global pandemics that flu A can, but it still causes serious illness and contributes significantly to flu season every year.
How Flu B Differs From Flu A
The flu viruses you hear about each winter belong to two types: influenza A and influenza B. Influenza A has dozens of subtypes (like H1N1 and H3N2) and constantly jumps between humans and animals, which gives it a vast genetic playground for producing new, unpredictable strains. Influenza B, by contrast, is essentially a human virus. Without that animal reservoir, it mutates at a substantially slower rate, and its evolution falls somewhere between the rapid, linear drift of influenza A and the more stable pattern of influenza C (a mild virus that rarely makes the news).
That slower mutation rate might sound like good news, but it comes with a twist. Multiple lineages of flu B can co-circulate at the same time, making it harder to predict which version will dominate in a given season. Currently, two main lineages exist: Victoria and Yamagata, named after the places where they were first identified. Victoria-lineage viruses have shown notable genetic changes in recent years, including deletions in the part of the virus that your immune system recognizes, which can help the virus dodge existing immunity.
Symptoms and Severity
Flu B causes the same core symptoms as flu A: fever, body aches, cough, sore throat, fatigue, and sometimes vomiting or diarrhea, especially in children. There’s a lingering perception that flu B is “milder,” but the data tells a different story. A CDC study of hospitalized adults found that flu B caused equally severe outcomes as flu A. Length of hospital stay, the proportion of patients admitted to intensive care, and even death rates were comparable between the two types. Clinicians are now advised not to treat flu B as less dangerous when weighing treatment options.
The onset tends to feel similar to flu A: rapid, often hitting within one to four days of exposure. You can go from fine to flat on your back in a matter of hours. The illness typically lasts about a week, though fatigue and cough can linger for two weeks or more.
Who Gets Hit Hardest
Flu B tends to circulate heavily among children and adolescents. During the 2024-25 flu season, 280 pediatric flu deaths were reported in the U.S., with flu B accounting for 38 of them (about 14%). In nearly every season since pediatric flu death surveillance began, flu A has been responsible for more child deaths than flu B, but that largely reflects the fact that flu A circulates more widely overall. Season to season, the proportion of pediatric deaths caused by flu B roughly mirrors its share of circulating viruses in the broader population.
Older adults, pregnant women, and people with chronic conditions like asthma, diabetes, or heart disease face elevated risks from flu B, just as they do from flu A. The virus doesn’t discriminate based on type when it leads to complications like pneumonia or organ inflammation.
Testing and Detection
Most people who get tested for the flu at a clinic or pharmacy encounter a rapid influenza diagnostic test (RIDT). These tests can distinguish between flu A and flu B, which is useful for tracking what’s circulating in your community. However, rapid tests are less sensitive for flu B than for flu A. The FDA requires these tests to detect flu B with at least 80% sensitivity, meaning roughly one in five flu B infections could produce a false negative on a rapid test.
If your rapid test comes back negative but your doctor strongly suspects the flu based on your symptoms and local outbreak data, a more accurate lab-based test (RT-PCR) can confirm or rule out infection. These molecular tests are the gold standard and catch cases that rapid tests miss.
Treatment Differences for Flu B
Antiviral medications work against both flu A and flu B, but they don’t work equally well. Research shows that flu B viruses are less susceptible to the most commonly prescribed antiviral (oseltamivir, sold as Tamiflu) compared to flu A viruses. This reduced effectiveness is especially notable in young children, where observational studies have consistently found lower clinical benefit from oseltamivir for flu B infections.
An alternative antiviral, zanamivir (an inhaled medication), appears to perform better against flu B in pediatric patients. Your doctor may factor in the specific virus type when choosing a treatment approach, which is one reason testing matters even when the symptoms look the same regardless of type. Antivirals work best when started within 48 hours of symptom onset, so early testing and early treatment go hand in hand.
Flu B and the Seasonal Vaccine
For years, flu vaccines came in two formats: trivalent (covering three strains) and quadrivalent (covering four, including both flu B lineages). That’s changing. The Yamagata lineage of flu B has not been detected in circulation since the early days of the COVID-19 pandemic, and the World Health Organization now recommends excluding it from vaccines. For the 2024-25 northern hemisphere season, the WHO advised that trivalent vaccines include a Victoria-lineage flu B strain and that new quadrivalent formulations drop the Yamagata component entirely.
This shift means the seasonal flu shot now focuses its flu B protection on the Victoria lineage alone. If the Yamagata lineage has truly gone extinct (as many virologists suspect), this simplification could improve vaccine effectiveness by allowing manufacturers to concentrate resources on the strains that are actually circulating. Getting vaccinated each year remains the most effective way to reduce your risk of severe illness from both flu A and flu B, since the specific strains in the vaccine are updated annually based on global surveillance data.
Why Flu B Still Matters
Flu B often plays second fiddle to flu A in media coverage and public awareness, partly because it can’t cause pandemics and partly because flu A circulates more widely in most seasons. But flu B can dominate in certain years or peak later in the season, catching communities off guard after flu A activity has waned. It causes the same range of serious complications, responds less reliably to the most common antiviral, and circulates heavily among school-age children. Treating it as an afterthought is a mistake the clinical data doesn’t support.